OrthoSensor today reported it raised $3.9 million in a new round of financing looking to bring in another $8.1 million before closing, according to an SEC filing.
Dania Beach, Fla.-based Orthosensor develops and produces the Verasense system, designed to aid surgeons measure proper placement and motion during total knee replacements. The system analyzes ligament balance and returns data the surgeon can use to aid them during the procedure.
Funds from the round came from 9 different anonymous investors, according to an SEC filing.
No terms or specific investors were mentioned, and the company has not discussed what the funds from the round will be used for.
In March, OrthoSensor said it closed out a $19 million Series C round it planned to use to commercialize its Verasense knee implant technology.
OrthoSensor said Bridger Healthcare and the Tullis Growth Fund participated in the round.
Earlier in March OrthoSensor said in a regulatory filing that it raised $17 million for Verasense, which is designed to help surgeons measure proper placement and motion during total knee replacement procedures.
OrthoSensor closed a $48 million Series B round in October 2013, just after its Verasense device gained a CE Mark approval in the European Union. The FDA granted 510(k) clearance to the Verasense device in June 2013.
The deal with Zimmer calls for the co-marketing of Verasense with Zimmer’s NextGen knee surgery platform; likewise, the Smith & Nephew agreement involves integrating Verasense with its Journey II and Legion knee implants.